Get started Log in

POLB — Poolbeg Pharma Share News

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapMomentum Trap

Brief: Poolbeg Partners With Biopharma For Development Of Optimised Oral Drug To Treat Metabolic Condition
17/10/2023 07:40
Brief: Poolbeg Pharma Says Notice Of Allowance For Patent Grant In Japan
20/09/2023 07:45
Immunomodulator I Patent Portfolio Strengthened
20/09/2023 07:00
Brief: Poolbeg Pharma PLC Announces Immunomodulator I Patent Opposition Withdrawal
19/09/2023 07:59
Interim results for the six months to 30 June 2023
13/09/2023 07:00
Board Appointment
24/05/2023 07:00
Annual Report & AGM Notice
12/04/2023 07:00
Results for the year ended 31 December 2022
30/03/2023 07:00
Notification of Major Holdings
10/03/2023 07:00
Notification of Major Holdings
09/03/2023 15:51
Brief: Poolbeg Pharma Says Polb 001 Patent Portfolio Was Granted U.S. Patent
08/03/2023 07:34
POLB 001 patent portfolio strengthened
08/03/2023 07:00
Brief: Poolbeg Pharma Says POLB 001 Treatment Exhibited Marked Reduction In Multiple Markers Of Systemic And Local Inflammation
02/03/2023 08:15
Strategic expansion of POLB 001 into oncology
16/01/2023 07:00
Second Price Monitoring Extn
09/01/2023 09:05
Price Monitoring Extension
09/01/2023 09:00
Positive Initial Data Analysis in POLB 001 Trial
09/01/2023 07:00
Brief: Poolbeg Pharma Identifies Potential Drug Candidates For Respiratory Syncytial Virus Infections
21/12/2022 07:28
Poolbeg identifies novel RSV drug candidates
21/12/2022 07:00
Metabolic diseases oral delivery licence signed
14/12/2022 07:00